Home › Acceleron Highlights Phase 3 Studies, New Clinical Results And Research Strategies At Research And Development Day Event
 

Keywords :   


Acceleron Highlights Phase 3 Studies, New Clinical Results And Research Strategies At Research And Development Day Event

2015-11-03 04:51:04| drugdiscoveryonline Home Page

Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, recently announced the phase 3 clinical trial designs for the luspatercept program in myelodysplastic syndromes (“MEDALIST” study) and beta-thalassemia (“BELIEVE” study), phase 1 preliminary results from the ACE-083 program, and its new IntelliTrapdrug discovery platform

Tags: day results research development

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
09.05Maryland Adopts PaintCare Program
09.05Society of Cosmetic Chemists Intermountain West to Host Healthy Bite Oral Care Symposium
09.05A.Celli and Akinal Tekstil Collaborate on Line Installation
09.05Record levels of shoplifting show signs of falling
09.05National Advertising Division Recommends Amyris Clean Beauty Modify Claim
09.05RTL Luxembourg deploys Verimatrix to protect auto racing from piracy
09.05Bank of England boss weighs in on UK economy row
09.05Roku and The Trade Desk announce data-driven streaming partnership
More »